21 February 2024 | Wednesday | News
Image Source | BioPharma APAC Resource Library
Thermo Fisher Scientific has unveiled the latest recipients of its Oncomine Clinical Research Grant, a prestigious accolade dedicated to advancing research in the realm of oncology. This announcement, made from Carlsbad, California, marks the seventh iteration of the grant program, which has been instrumental in promoting high-quality molecular profiling in cancer research. The grant aims to democratize precision medicine by supporting investigator-initiated studies.
Since its inception in 2020, the Oncomine Clinical Research Grant program has awarded up to $200,000 in reagents and funding to 22 distinct research projects worldwide. These projects span a diverse range of topics within oncology, including molecular profiling in solid tumors, pediatric oncology, hemato-oncology, immune-oncology, and liquid biopsy. This initiative underscores Thermo Fisher's commitment to enhancing clinical outcomes through next-generation sequencing (NGS) technologies.
Meet the Latest Grant Recipients
Based on the last call for proposals in Spring 2023, the following researchers and projects have been selected as the most recent grant recipients:
Recipients also had the opportunity to present their findings at an Oncomine Scientific Gala, showcasing the potential of NGS testing in oncology. The program has facilitated significant research outcomes, such as a study on pregnancy-associated breast cancer (PABC), highlighting its contribution to understanding and treating complex conditions.
The next call for proposals will open in March 2024, inviting research that explores the molecular landscape of tumors and the role of molecular testing in enhancing treatment precision. Thermo Fisher Scientific continues to support the oncology research community through these grants, reinforcing its dedication to advancing precision oncology.
Most Read
Bio Jobs
News
Editor Picks